54187-04-1 Usage
Description
Rilmenidine, also known by its brand name Hyperium, is a novel antihypertensive agent with a selective alpha2-agonist/antagonist profile. It is an I1-imidazoline binding site ligand and a2-adrenoceptor agonist, exhibiting higher I1 vs. a2 selectivity than clonidine. Rilmenidine is characterized by its water-soluble chemical properties and is reportedly useful in the management of mild to moderate hypertension. Its primary indication is possible due to the clear dissociation of its antihypertensive activity from other neuropharmacological effects.
Uses
Used in Pharmaceutical Industry:
Rilmenidine is used as an antihypertensive agent for the management of mild to moderate hypertension. Its selective alpha2-agonist/antagonist profile and higher I1 vs. a2 selectivity contribute to its effectiveness in treating blood pressure-related conditions.
Used in Research and Development:
Rilmenidine is used as a research compound for studying the effects of I1-imidazoline binding site ligands and a2-adrenoceptor agonists on blood pressure regulation and other related physiological processes. This helps in the development of new drugs and therapies for hypertension and other cardiovascular conditions.
Used in Clinical Trials:
Rilmenidine is used as a test subject in clinical trials to evaluate its safety, efficacy, and potential side effects when used for the management of mild to moderate hypertension. These trials provide valuable data for the development of new treatment options and the improvement of existing ones.
Originator
Servier (France)
Biological Activity
I 1 -imidazoline binding site selective ligand and α 2 -adrenoceptor agonist. Possesses greater I 1 vs α 2 selectivity than the prototypical compound, clonidine.
Metabolic pathway
In short-term rat hepatocyte cultures, oxaminozoline is
metabolized and its four metabolites resulting from
oxidation or hydrolysis are identified, three of which
are identical to those reported in vivo. The presence of
an additional minor metabolite in culture may be due
to the higher metabolic rate of oxaminozoline in this
model system.
Check Digit Verification of cas no
The CAS Registry Mumber 54187-04-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,4,1,8 and 7 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 54187-04:
(7*5)+(6*4)+(5*1)+(4*8)+(3*7)+(2*0)+(1*4)=121
121 % 10 = 1
So 54187-04-1 is a valid CAS Registry Number.
InChI:InChI=1/2C10H16N2O.C4H4O4/c2*1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10;5-3(6)1-2-4(7)8/h2*7-9H,1-6H2,(H,11,12);1-2H,(H,5,6)(H,7,8)/b;;2-1+
54187-04-1Relevant articles and documents
Cyclopropylamines as pharmaceuticals
-
, (2008/06/13)
The present invention relates to cyclopropylmethyl amines substituted by a heterocyclic radical. More particularly the heterocyclic radical is a nitrogen containing ring with 5, 6 or 7 links interrupted by another hetero atom selected from the group consisting of oxygen, sulphur and imino--NH-- The invention also relates to the acid addition salts thereof with physiologically compatible mineral or organic acids. The invention extends to the processes for making them and the intermediates produced hereto. The invention also includes the pharmaceutical compositions incorporating as active ingredient at least one compound of the invention with an inert carrier. The compounds have therapeutic utility namely on the cardio-vascular diseases and on the neuro-psychological disturbances.